Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 50.00 | |
10 mg | In stock | $ 60.00 | |
25 mg | In stock | $ 126.00 | |
50 mg | In stock | $ 225.00 | |
100 mg | In stock | $ 378.00 |
Description | BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively. |
Targets&IC50 | PDE7B:12 μM, PDE7A:0.15 μM, PDE3:490 μM, PDE4:62 μM |
In vitro | BRL-50481 marginally increases cAMP levels (19.1±6.2% of the IBMX response at 300 μM) but demonstrates lower potency. At a concentration of 30 μM, BRL-50481 does not independently hinder proliferation but significantly enhances the efficacy of rolipram in this regard. Similarly, it does not affect IL-15-driven proliferation alone, yet amplifies rolipram’s inhibitory properties. A 30-minute pretreatment of human monocytes with BRL-50481 exhibits a minor inhibitory impact (~2 to 10%) on TNFα production across all examined concentrations but boosts the suppressive action of PGE2 on LPS-induced TNFα release. Alone, BRL-50481 has a negligible influence on κB-dependent transcription (5.6±1.9% inhibition at 30 μM) and does not bolster rolipram’s effectiveness (maximum inhibition, 52.9±2.7%; pIC30 value of 5.33±0.12). However, BRL-50481 dose-dependently curtails LPS-induced TNFα secretion in monocytes where PDE7A1 is elevated (21.7±1.6% inhibition at 30 μM after 12 hours) [2]. |
Cell Research | MOLT-4 cells in 96-well plates are treated for 30 min with BRL-50481. The cAMP content is then determined by an immuno-specific ELISA. Results are expressed as a percentage of the response affected by 100 μM IBMX[2]. |
Molecular Weight | 244.27 |
Formula | C9H12N2O4S |
CAS No. | 433695-36-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mg/mL
DMSO: 100 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BRL-50481 433695-36-4 Metabolism PDE inhibit BRL50481 Inhibitor BRL 50481 Phosphodiesterase (PDE) inhibitor